ResearcherKanagawa Cancer CenterActive in the last 2 years
Kota Washimi
Matched on ORCID iD 0000-0001-6353-776X; OpenAlex author ID A5031497902, A5055159531. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 4
- Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
- Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
- Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. Co-author DOI 10.1111/pin.13416↗
- [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. Co-author PMID 27760963↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Makoto Ueno · 4 shared papers, 2016–2026 · strength 0.68
- Paper Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. DOI 10.1245/s10434-026-19380-z↗
- Paper Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outc… DOI 10.1245/s10434-025-18186-9↗
- Paper Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. DOI 10.1111/pin.13416↗
- Yohei Miyagi · 3 shared papers, 2024–2026 · strength 0.63
- Paper Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. DOI 10.1245/s10434-026-19380-z↗
- Paper Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outc… DOI 10.1245/s10434-025-18186-9↗
- Paper Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. DOI 10.1111/pin.13416↗
- Satoshi Kobayashi · 3 shared papers, 2024–2026 · strength 0.63
- Paper Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. DOI 10.1245/s10434-026-19380-z↗
- Paper Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outc… DOI 10.1245/s10434-025-18186-9↗
- Paper Evaluation of pancreatic cancer specimens for comprehensive genomic profiling. DOI 10.1111/pin.13416↗
- Masaaki Murakawa · 3 shared papers, 2016–2026 · strength 0.49
- Paper Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. DOI 10.1245/s10434-026-19380-z↗
- Paper Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outc… DOI 10.1245/s10434-025-18186-9↗
- Paper [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. PMID 27760963↗
- Soichiro Morinaga · 3 shared papers, 2016–2026 · strength 0.49
- Paper Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. DOI 10.1245/s10434-026-19380-z↗
- Paper Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outc… DOI 10.1245/s10434-025-18186-9↗
- Paper [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. PMID 27760963↗
- Yuto Kamioka · 2 shared papers, 2025–2026 · strength 0.44
- Shinnosuke Kawahara · 2 shared papers, 2025–2026 · strength 0.44
- Naoto Yamamoto · 2 shared papers, 2024–2025 · strength 0.39
- Yukihiko Hiroshima · 2 shared papers, 2024–2025 · strength 0.39
- Mariko Kamiya · 1 shared paper, 2026 · strength 0.24
- Shiro Koizume · 1 shared paper, 2026 · strength 0.24
- Toru Aoyama · 1 shared paper, 2025 · strength 0.20
- Robert M. Hoffman · 1 shared paper, 2025 · strength 0.20
- Manabu Morimoto · 1 shared paper, 2016 · strength 0.05
- Toru Aoyama · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.